Delve into the fascinating link between T-cell receptor dynamics and melanoma survival. Discover how the overexpression of renalase-1 negatively impacts patient outcomes. Learn about the potential of targeting this protein to enhance immunotherapy. Researchers highlight the intriguing chemical interactions between TCR CDR3 sequences and renalase-1, revealing promising pathways for future cancer treatments. This captivating discussion opens new doors for improving melanoma patient survival through innovative strategies.

Justine Paris, a metastatic disease researcher from Université Paris Cité, and Guilhem Bousquet, a medical oncologist at Université Sorbonne Paris Nord, dive into groundbreaking findings in cancer research. They discuss PROM2 as a vital predictive biomarker for stage III melanoma, revealing its link to distant metastases and survival outcomes. Their innovative in vivo model mimics the runaway metastatic process, shedding light on mechanisms like epithelial-to-mesenchymal transition and ferroptosis resistance, with implications for renal and breast cancers as well.

Chantal L. Duurland, Thijs de Gunst, Harm C. den Boer, and their team explore a groundbreaking approach to cancer treatment using the INT-1B3 miR-193a-3p mimic. This innovative therapy enhances T cell immunity and induces immunogenic cell death, showing potential for long-term tumor resistance. The researchers discuss the implications of their findings on the tumor microenvironment and how this method could revolutionize anti-tumor strategies. Expect insights into the future of immunotherapy and its transformative potential in cancer care.

Researchers dive into the roles of Macrophage Migration Inhibitory Factor (MIF) and D-dopachrome Tautomerase (DDT) in melanoma. They explore how these factors might influence tumor progression and patient survival. The study reveals MIF as a potential target for immune therapy in resistant cases. Additionally, insights from a comprehensive analysis of patient samples suggest that MIF and DDT levels could serve as crucial prognostic markers. Innovative approaches in gene expression research are paving the way for future therapeutic strategies.

Benigno C. Valdez and his fellow researchers, Apostolia M. Tsimberidou, Bin Yuan, Yago Nieto, Mehmet A. Baysal, Abhijit Chakraborty, Clark R. Andersen, and Borje S. Andersson, delve into a groundbreaking triple-drug combination against pancreatic cancer. They reveal how the synergistic effects of histone deacetylase inhibitors, PARP inhibitors, and decitabine can enhance treatment efficacy. This innovative strategy challenges conventional therapies and highlights the importance of collaboration in advancing personalized cancer treatment.

Luisa N. Dominguez Aldama, Eric Karlins, and Xiaoping Sun, leading researchers in mastocytosis genetics, delve into the intriguing KIT M541L variant. They reveal that this variant is often associated with systemic mastocytosis, particularly in pediatric cases. The discussion uncovers how this mutation compares in prevalence between patients and a control group, alongside its surprising lack of significant symptom differences. Listeners will gain insights into how genetic factors influence mastocytosis diagnosis and patient experiences.

BUFFALO, NY - July 22, 2024 – Oncotarget proudly welcomes new members to our esteemed Editorial Board, including our new Co-Editor-in-Chief, Dr. Wafik S. El-Deiry. Joining Dr. El-Deiry on Oncotarget’s Editorial Board are Dr. Trever Bivona, Dr. Phillip Buckhaults, Dr. Fred Bunz, Dr. Jonathan Chernoff, Dr. Stephen G. Chun, Dr. Nathan Dolloff, Dr. Peiwen Fei, Dr. Justin D. Lathia, Dr. Bora Lim, Dr. Jia (Jenny) Liu, Dr. Hui-Wen Lo, Dr. Emil Lou, Dr. Anirban Maitra, Dr. Ruben A. Mesa, and Dr. Yashbir Singh. To learn more about our outstanding members, please visit our Editorial Board page. In celebration of the new additions to Oncotarget’s Editorial Board, we are excited to offer a special discount of 50% on all publication fees until the end of the year. This is our way of saying thank you to our supporters! To learn about how to publish with Oncotarget, please visit our Editorial Policies page. About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Discover groundbreaking research on combining pembrolizumab with soluble EphB4-HSA to tackle HPV-negative head and neck cancer. The clinical trial reveals a significant 24% overall response rate, offering hope to patients facing limited treatment options. The conversation touches on the safety profile of this innovative therapy, which aligns with previous studies, highlighting its promise in improving outcomes for those with metastatic cancer. Tune in for insights into future treatment possibilities for this challenging disease.

Researcher Hirotaka Matsui from the National Cancer Center Hospital in Tokyo discusses genetic predisposition in myeloid neoplasms and the role of DDX41 in myeloid leukemogenesis. The podcast explores the unique disease characteristics associated with DDX41 variants.

Researchers from Radboud University Medical Center discuss the importance of early on-treatment ctDNA measurements in mCRPC, identifying patients who benefit from specific therapies like PARPi or LuPSMA in first-line treatment with ARPIs.